Within our cohort of 184 patients with central high-grade osteosarcomas who received neo-adjuvant chemotherapy, FGFR1 gene amplification was exclusively detected among the “poor responder” group and represented 17.4% of patients in this group. This evidence concerns the gene FGFR1 and osteosarcoma.